Cargando…

Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis

AIMS: An increasing body of evidence suggests that drug-coated balloon (DCB) angioplasty represents a valuable option for revascularization in selected patients with coronary bifurcation disease. However, there remains a paucity of real-world observational evidence on the efficacy of DCB in left mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Liang, Lu, Wenjie, Han, Zhanying, Pan, Sancong, Wang, Xi, Shan, Yingguang, Peng, Meng, Qin, Xiaofei, Sun, Guoju, Zhang, Peisheng, Dong, Jianzeng, Qiu, Chunguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669294/
https://www.ncbi.nlm.nih.gov/pubmed/36407423
http://dx.doi.org/10.3389/fcvm.2022.1028007
_version_ 1784832066906488832
author Pan, Liang
Lu, Wenjie
Han, Zhanying
Pan, Sancong
Wang, Xi
Shan, Yingguang
Peng, Meng
Qin, Xiaofei
Sun, Guoju
Zhang, Peisheng
Dong, Jianzeng
Qiu, Chunguang
author_facet Pan, Liang
Lu, Wenjie
Han, Zhanying
Pan, Sancong
Wang, Xi
Shan, Yingguang
Peng, Meng
Qin, Xiaofei
Sun, Guoju
Zhang, Peisheng
Dong, Jianzeng
Qiu, Chunguang
author_sort Pan, Liang
collection PubMed
description AIMS: An increasing body of evidence suggests that drug-coated balloon (DCB) angioplasty represents a valuable option for revascularization in selected patients with coronary bifurcation disease. However, there remains a paucity of real-world observational evidence on the efficacy of DCB in left main (LM) true bifurcation lesion. We compared clinical and angiographic outcomes of hybrid [DCB + drug-eluting stent (DES)] versus DES-only strategy (provisional stenting or two-stent strategies) in de novo LM true bifurcated lesions. METHODS: The primary endpoint was the 2-year composite rate of target lesion failure (TLF): cardiac death, target vessel myocardial infarction (TVMI), or clinically driven target lesion revascularization (CD-TLR). A routine 1-year angiographic follow-up was scheduled. Propensity-score matching was utilized to assemble a cohort of patients with similar baseline characteristics. RESULTS: Among 1077 eligible patients, 199 who received DCB treatment and 398 who were assigned to DES therapy had similar propensity scores and were included in the analysis. TLF within 2 years occurred in 13 patients (7.56%) assigned to DCB group, and 52 patients (14.36%) assigned to DES group (odds ratio: 0.487; 95% confidence interval: 0.258–0.922; P = 0.025; Log-rank P = 0.024). Compared with the DES group, the DCB group resulted in a lower rate of CD-TLR (2.91% vs. 9.42%; P = 0.007). Cardiac death, TVMI, all-cause mortality, and stent thrombosis were comparable between both groups. Patients treated with DES-only were associated with a higher late lumen loss (0.42 ± 0.62 mm vs. 0.13 ± 0.42 mm, P < 0.001) compared with the DCB group at 1 year. In sensitivity analysis, the DCB group also presented a lower incidence of TLF, CD-TLR and stent thrombosis both compared to the two-stent strategy and compared to provisional stenting (Ps < 0.05). CONCLUSION: The 2-year results of PCI utilizing DCB for LM true bifurcation lesions are superior to employing DES alone in terms of safety and effectiveness.
format Online
Article
Text
id pubmed-9669294
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96692942022-11-18 Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis Pan, Liang Lu, Wenjie Han, Zhanying Pan, Sancong Wang, Xi Shan, Yingguang Peng, Meng Qin, Xiaofei Sun, Guoju Zhang, Peisheng Dong, Jianzeng Qiu, Chunguang Front Cardiovasc Med Cardiovascular Medicine AIMS: An increasing body of evidence suggests that drug-coated balloon (DCB) angioplasty represents a valuable option for revascularization in selected patients with coronary bifurcation disease. However, there remains a paucity of real-world observational evidence on the efficacy of DCB in left main (LM) true bifurcation lesion. We compared clinical and angiographic outcomes of hybrid [DCB + drug-eluting stent (DES)] versus DES-only strategy (provisional stenting or two-stent strategies) in de novo LM true bifurcated lesions. METHODS: The primary endpoint was the 2-year composite rate of target lesion failure (TLF): cardiac death, target vessel myocardial infarction (TVMI), or clinically driven target lesion revascularization (CD-TLR). A routine 1-year angiographic follow-up was scheduled. Propensity-score matching was utilized to assemble a cohort of patients with similar baseline characteristics. RESULTS: Among 1077 eligible patients, 199 who received DCB treatment and 398 who were assigned to DES therapy had similar propensity scores and were included in the analysis. TLF within 2 years occurred in 13 patients (7.56%) assigned to DCB group, and 52 patients (14.36%) assigned to DES group (odds ratio: 0.487; 95% confidence interval: 0.258–0.922; P = 0.025; Log-rank P = 0.024). Compared with the DES group, the DCB group resulted in a lower rate of CD-TLR (2.91% vs. 9.42%; P = 0.007). Cardiac death, TVMI, all-cause mortality, and stent thrombosis were comparable between both groups. Patients treated with DES-only were associated with a higher late lumen loss (0.42 ± 0.62 mm vs. 0.13 ± 0.42 mm, P < 0.001) compared with the DCB group at 1 year. In sensitivity analysis, the DCB group also presented a lower incidence of TLF, CD-TLR and stent thrombosis both compared to the two-stent strategy and compared to provisional stenting (Ps < 0.05). CONCLUSION: The 2-year results of PCI utilizing DCB for LM true bifurcation lesions are superior to employing DES alone in terms of safety and effectiveness. Frontiers Media S.A. 2022-11-03 /pmc/articles/PMC9669294/ /pubmed/36407423 http://dx.doi.org/10.3389/fcvm.2022.1028007 Text en Copyright © 2022 Pan, Lu, Han, Pan, Wang, Shan, Peng, Qin, Sun, Zhang, Dong and Qiu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Pan, Liang
Lu, Wenjie
Han, Zhanying
Pan, Sancong
Wang, Xi
Shan, Yingguang
Peng, Meng
Qin, Xiaofei
Sun, Guoju
Zhang, Peisheng
Dong, Jianzeng
Qiu, Chunguang
Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis
title Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis
title_full Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis
title_fullStr Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis
title_full_unstemmed Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis
title_short Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis
title_sort drug-coated balloon in the treatment of coronary left main true bifurcation lesion: a patient-level propensity-matched analysis
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669294/
https://www.ncbi.nlm.nih.gov/pubmed/36407423
http://dx.doi.org/10.3389/fcvm.2022.1028007
work_keys_str_mv AT panliang drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT luwenjie drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT hanzhanying drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT pansancong drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT wangxi drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT shanyingguang drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT pengmeng drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT qinxiaofei drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT sunguoju drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT zhangpeisheng drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT dongjianzeng drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis
AT qiuchunguang drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis